Celcuity

Celcuity Financial Debt Ratio

The Financial Debt Ratio of Celcuity (CELC) as of Nov 11, 2026 is 69.00 %. In the previous year, Financial Debt Ratio was 39.87 % — a change of 73.06% (higher).

Financial Debt Ratio

69.00 %

YoY

73.06%

Last updated:

Financial Debt Ratio of Celcuity is 2025 69.00 % . Financial Debt Ratio of Celcuity was 2024 39.87 % . It decreases by 73.06% higher compared to the previous year.

The Celcuity Financial Debt Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Debt Ratio
Date
Financial Debt Ratio
Jan 1, 2018
0.00 USD
Jan 1, 2019
0.00 USD
Jan 1, 2020
0.00 USD
Jan 1, 2021
17.00 USD
Jan 1, 2022
19.92 USD
Jan 1, 2023
19.37 USD
Jan 1, 2024
39.87 USD
Jan 1, 2025
69.00 USD
The Celcuity Financial Debt Ratio history
YEARFinancial Debt RatioYoY
69.00 %+73.06%
39.87 %+105.85%
19.37 %-2.77%
19.92 %+17.21%
17.00 %—
0.00—
0.00—
0.00—
0.00—
0.00—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Celcuity Stock analysis

What does Celcuity do? Celcuity Inc is a biotechnology company founded by Brian Sullivan in 2012. The company is headquartered in Minneapolis, USA. The business model of Celcuity is based on researching and developing new diagnostic and treatment methods for various types of cancer. The company utilizes a proprietary technology platform called CELx, which enables the analysis of cancer cell signaling pathways and the development of individualized treatment strategies. Celcuity specializes in the development of diagnostics and personalized therapies based on individual cancer cell signaling pathways. The company operates in two divisions: 1. Diagnostics division: Celcuity's diagnostics division focuses on identifying new cancer markers and biomarkers for early detection of cancer and the development of individualized treatment strategies. 2. Therapy division: Celcuity's therapy division specializes in the development of personalized therapies based on individual cancer cell signaling pathways. Celcuity currently offers two products based on the CELx technology platform: 1. CELx HUB: CELx HUB is a cloud-based software that allows doctors and researchers to analyze cancer samples and develop individualized treatment strategies. 2. CELx TIL: CELx TIL is a diagnostic tool that measures the presence of tumor cells in the immune system of cancer patients. In summary, Celcuity Inc is a leader in the field of personalized cancer therapy based on individual cancer cell signaling pathways. The company has found a niche in this growing market and has a unique technology platform that allows it to serve its customers effectively. With its products and services, Celcuity is helping to revolutionize cancer treatment and improve the quality of life for cancer patients worldwide. Celcuity is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celcuity stock

Financial Debt Ratio of Celcuity is 69.00 % in 2025.

Financial Debt Ratio of Celcuity changed from 39.87 % to 69.00 %, representing a 73.06% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Debt Ratio Celcuity since 2006 – with annual values, charts, and detailed analysis.

The financial debt ratio measures interest-bearing financial debt as a percentage of total assets. It isolates funded debt from trade and other non-financial obligations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Debt Ratio's Celcuity with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Celcuity

All Key Metrics — Celcuity